Acrobiosystems for English
icon_bulk_orderBulk inquiry/Quick order
0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > NPR1

NPR1

Brief Information

Name:Natriuretic peptide receptor 1
Target Synonym:EC:4.6.1.2,Atrionatriuretic Peptide Receptor A,Natriuretic Peptide Receptor A,ANPRA,Atrial Natriuretic Peptide Receptor 1,Natriuretic Peptide A Type Receptor,Testicular Tissue Protein Li 20,EC 4.6.1.2,GUCY2A,GUC2A,ANPa,NPRA,GC-A,NPR-A,NPR1,Guanylate cyclase A,ANP-A,Natriuretic Peptide Receptor 1,Atrial Natriuretic Peptide Receptor Type A,ANPR-A,Natriuretic Peptide Receptor A/Guanylate Cyclase A (Atrionatriuretic Peptide Receptor A)
Number of Launched Drugs:3
Number of Drugs in Clinical Trials:9
Lastest Research Phase:Approved

Product ListCompare or Buy

ACRO Quality

Part of Bioactivity data

NP1-H82E9-MALS-HPLC
Biotinylated Human NPR1, His,Avitag (Cat. No. ) MALS images

The purity of Biotinylated Human NPR1, His,Avitag (Cat. No. NP1-H82E9) is more than 85% and the molecular weight of this protein is around 65-80 kDa verified by SEC-MALS.

  • Background
    Receptor for the atrial natriuretic peptide NPPA/ANP and the brain natriuretic peptide NPPB/BNP which are potent vasoactive hormones playing a key role in cardiovascular homeostasis. Has guanylate cyclase activity upon binding of the ligand.
  • Clinical and Translational Updates
      
  • Please contact us via TechSupport@acrobiosystems.com if you have any question on this product.

    NP1-H5259-MALS-HPLC
    NPR1 MALS images

    The purity of Human NPR1, Fc Tag (Cat. No. NP1-H5259) is more than 90% and the molecular weight of this protein is around 165-190 kDa verified by SEC-MALS.

Synonym Name

Atrial natriuretic peptide receptor 1,NPR1,NPRA,GC-A,ANPRA,NPR-A

Background

Receptor for the atrial natriuretic peptide NPPA/ANP and the brain natriuretic peptide NPPB/BNP which are potent vasoactive hormones playing a key role in cardiovascular homeostasis. Has guanylate cyclase activity upon binding of the ligand.

Clinical and Translational Updates

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Carperitide SUN-4936; SUN-4936h; SUN-4936r; SUN-Y4936r; alpha-hANP; ANF (99-126); ANP (99-126); CDD (99-126) Approved Daiichi Sankyo Co Ltd HANP Japan Heart Failure Daiichi Sankyo Co Ltd 1995-01-20 Heart Failure; Respiratory Distress Syndrome, Adult; Cardiomyopathies Details
Recombinant human brain natriuretic peptide (Tibet Rhodiola) Approved Tibet Rhodiola Pharmaceutical Holding Company 新活素 Mainland China Heart Failure Chengdu Rhodiola Bio-Pharmaceutical Co Ltd 2005-04-11 Heart Failure; Acutely decompensated congestive heart failure Details
Sodium Nitroprusside SNP Approved F. Hoffmann-La Roche Ltd Nipride, Nitriate, Nitropress Mainland China Heart Failure; Hypertension China Resources Double-Crane Pharmaceutical Co Ltd 1974-05-10 Hypotension; Schizophrenia; Heart Failure; Hypertension Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
REGN-5381 REGN-5381 Phase 2 Clinical Regeneron Pharmaceuticals Inc Heart Failure Details
Recombinant human brain natriuretic peptide(Shijiazhuang wotai) Phase 1 Clinical Shijiazhuang wotai Biotechnology Co Ltd Heart Failure; Acutely decompensated congestive heart failure Details
PL-3994 PL-3994 Phase 2 Clinical Palatin Technologies Inc Heart Failure; Hypertension; Asthma Details
XXB-750 XXB-750 Phase 2 Clinical Novartis Pharma Ag Heart Failure; Hypertension Details
Recombinant human brain natriuretic peptide (Shanghai Jiao Tong University) Phase 3 Clinical Shanghai Jiaotong University Heart Defects, Congenital; Tetralogy of Fallot Details
REGN-7544 REGN-7544; REGN7544 Phase 1 Clinical Regeneron Pharmaceuticals Inc Details
Recombinant human brain natriuretic peptide (Suzhou Landing Bioteh) Phase 1 Clinical Suzhou RxD Biopharmaceutical Co Ltd Heart Failure Details
Nesiritide BNP-32 (human); JNS-004; hBNP; SC-70400 Phase 2 Clinical Johnson & Johnson Myocardial Ischemia; Hyperemia; Heart Failure; Renal Insufficiency; Acutely decompensated congestive heart failure; Sleep Disorders, Circadian Rhythm; Hypertension; Dyspnea; Coronary Disease; Cardiomyopathies; Hyperinsulinism; Cardiovascular Diseases; Obesity; Diabetes Mellitus; Heart Failure, Systolic Details
GNP Phase 2 Clinical Guangzhou Leien Kangya Biomedical Technology Co Ltd Heart Failure; Acutely decompensated congestive heart failure Details

This web search service is supported by Google Inc.

totop
Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
Fax
Fax
+1 888-377-6111
Address
Address
1 Innovation Way, Newark, DE 19711, USA

Leave a message